TTI Stock Overview
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Thiogenesis Therapeutics, Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.74 |
| 52 Week High | CA$1.06 |
| 52 Week Low | CA$0.60 |
| Beta | 0.57 |
| 1 Month Change | -3.90% |
| 3 Month Change | -14.94% |
| 1 Year Change | 7.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 48.00% |
Recent News & Updates
Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation
Aug 25
Shareholder Returns
| TTI | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -1.3% | -6.4% | -2.1% |
| 1Y | 7.2% | -35.6% | 3.6% |
Return vs Industry: TTI exceeded the Canadian Biotechs industry which returned -33.7% over the past year.
Return vs Market: TTI exceeded the Canadian Market which returned 3.2% over the past year.
Price Volatility
| TTI volatility | |
|---|---|
| TTI Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: TTI's share price has been volatile over the past 3 months.
Volatility Over Time: TTI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Patrice Rioux | www.thiogenesis.com |
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet medical needs. Its lead product candidate under development is TTI-0102, a prodrug consisting of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, Rett syndrome, and pediatric non-alcoholic fatty liver diseases. The company is headquartered in Toronto, Canada.
Thiogenesis Therapeutics, Corp. Fundamentals Summary
| TTI fundamental statistics | |
|---|---|
| Market cap | CA$32.23m |
| Earnings (TTM) | -CA$3.44m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.6x
P/E RatioIs TTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TTI income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.44m |
| Earnings | -CA$3.44m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.077 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TTI perform over the long term?
See historical performance and comparison